Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX in Resectable Pancreatic Cancer
NCT02178709Phase 2Completed
- Sponsor
- Indiana University
- Start
- Jun 2014
- Primary completion
- Feb 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil in pancreatic ductal adenocarcinoma (PDAC), sponsored by Indiana University. Started Jun 2014; status: completed.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02178709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178709.